Antimicrobial Susceptibility of Bacteria That Cause Bovine Respiratory Disease Complex in Alberta, Canada

R. Michele Anholt1*, Cassidy Klima2, Nick Allan3, Heather Matheson-Bird3, Crystal Schatz4, Praseeda Ajitkumar5, Simon JG Otto6,7, Delores Peters6, Karin Schmid8, Merle Olson9, Tim McAllister2 and Brenda Ralston6

1 POV Inc., Airdrie, AB, Canada, 2 Agriculture and Agri-Food Canada, Lethbridge, AB, Canada, 3 Chinook Contract Research Inc., Airdrie, AB, Canada, 4 Bow Valley Research Inc., Calgary, AB, Canada, 5 Institute for Applied Poultry Technologies, Airdrie, AB, Canada, 6 Alberta Ministry of Agriculture and Forestry, Airdrie, AB, Canada, 7 School of Public Health, University of Alberta, Edmonton, AB, Canada, 8 Alberta Beef Producers, Calgary, AB, Canada, 9 Alberta Veterinary Laboratories Ltd, Calgary, AB, Canada

Bovine respiratory disease (BRD) is the most important illness of feedlot cattle. Disease management targets the associated bacterial pathogens, Mannheimia haemolytica, Mycoplasma bovis, Pasteurella multocida, Histophilus somni, and Trueperella pyogenes. We conducted a cross-sectional study to measure the frequencies of antimicrobial-resistant BRD pathogens using a collaborative network of veterinarians, industry, government, and a diagnostic laboratory. Seven private veterinary practices in southern Alberta collected samples from both living and dead BRD-affected animals at commercial feedlots. Susceptibility testing of 745 isolates showed that 100% of the M. haemolytica, M. bovis, P. multocida, and T. pyogenes isolates and 66.7% of the H. somni isolates were resistant to at least one antimicrobial class. Resistance to macrolide antimicrobials (90.2% of all isolates) was notable for their importance to beef production and human medicine. Multidrug resistance (MDR) was high in all target pathogens with 47.2% of the isolates resistant to four or five antimicrobial classes and 24.0% resistance to six to nine classes. We compared the MDR profiles of isolates from two feedlots serviced by different veterinary practices. Differences in the average number of resistant classes were found for M. haemolytica ($p < 0.001$) and P. multocida ($p = 0.002$). Compared to previous studies, this study suggests an increasing trend of resistance in BRD pathogens against the antimicrobials used to manage the disease in Alberta. For the veterinary clinician, the results emphasize the importance of ongoing susceptibility testing of BRD pathogens to inform treatment protocols. Surveillance studies that collect additional epidemiological information and manage sampling bias will be necessary to develop strategies to limit the spread of resistance.

Keywords: antimicrobial resistance, bovine respiratory disease complex, Mannheimia haemolytica, Mycoplasma bovis, Pasteurella multocida, Haemophilus somnus, Trueperella pyogenes

INTRODUCTION

Bovine respiratory disease (BRD) in newly received calves continues to be the most predominant health issue for North American beef production, with incidences that range from 5 to 44% and estimated costs to producers at $13.90 per animal (1). Mannheimia haemolytica, Mycoplasma bovis,
Pasteurella multocida, Histophilus somni, and Trueperella pyogenes are all opportunistic bacterial agents that can be associated with BRD: the roles of each in BRD infections have been extensively reviewed elsewhere (2, 3). Microbiological testing adds to production costs and time-to-results limits the feasibility of using these tests to inform real-time treatment decisions. Consequently, the empirical use of broad-spectrum antimicrobials is currently considered essential for the prevention and treatment of BRD (4).

There is evidence of declining efficacy of the antimicrobials commonly used to manage these pathogens (5–7). Resistance to multiple antimicrobial classes has been associated with large, mobile genetic elements in M. haemolytica and P. multocida (8–10). Poor response to antimicrobial therapy threatens livestock health and welfare, may lead to increased antimicrobial use (AMU), increases production costs, and potentially contributes to the dissemination of antimicrobial-resistant genes to other bacteria in cattle and possibly the environment (11, 12).

Knowledge of regional antimicrobial sensitivity patterns can help veterinarians design effective treatment protocols, inform management strategies to support responsible antimicrobial stewardship, reduce costs of production, and improve animal health and welfare. The objectives of this study were to (i) investigate the feasibility of a collaborative network of private practice veterinarians, industry representatives, government agencies, and a diagnostic laboratory for monitoring antimicrobial resistance (AMR) in beef cattle and (ii) conduct a cross-sectional study to describe the pathogens isolated in clinical BRD cases and the frequency of AMR in the isolated pathogens.

MATERIALS AND METHODS

Target Population and Sample Collection

Sixty commercial feedlots located in southern Alberta, managed by seven private veterinary practices, and ranging in capacity from 2,000 to 25,000 head, participated in the study. An estimate of the sample size needed to assess AMR to BRD pathogens was calculated. The assumptions were: (i) significance level, 0.05, (ii) a priori estimate of the proportion AMR positive, conservatively = 0.05, (iii) precision = 0.05. We estimated a 60% recovery of a targeted BRD pathogen from the collected samples. The estimated number of cattle to be sampled was 642. Sampling occurred between September 2014 and March 2015 and included all types, ages, and sexes of cattle.

Veterinarians and feedlot managers who participated in this study did so voluntarily with the assurance that we would respect the anonymity and confidentiality of their data. Most of the cattle sampled in this study had died as a result of disease. Live animal sampling was within the veterinary scope of practice for commercial beef production in Canada.

Samples were collected from both morbid and clinically healthy cattle. Morbid cattle were sampled if pulled for treatment and diagnosed chute-side with BRD based on elevated rectal temperature (>40°C) and clinical signs consistent with the disease. Guarded, deep nasopharyngeal swabs (Jorgensen Laboratories, Inc., Loveland, CO, USA) were employed for live animal sampling. Swabs were stored in Amies" bacterial transport medium (Starplex Scientific, Inc., Etobicoke, ON, USA) at 4°C until delivered to the diagnostic laboratory within 3 days of sampling. Samples were frozen and stored at −20°C until processing if delivery time was projected to exceed 72 h. Mortalities were sampled based on gross pathological evidence of infectious pneumonia at postmortem. Samples collected at postmortem included: lung tissue; nasal, tracheal, and laryngeal swabs; pleural fluid; heart or pericardium; joint fluid; peritoneal fluid and tissue; and abscesses. These were collected aseptically avoiding contamination by environmental bacteria and stored in sterile containers without media at 4°C until delivered to the diagnostic laboratory within 3 days of sampling from participating practices. Descriptive and clinical information regarding the sampled animal were also collected if possible (Table 1). All samples were processed at the Institute of Applied Poultry Technologies in Airdrie, AB, Canada.

Sample Processing

Swab samples were inoculated directly onto Tryptic Soy Agar containing 5% blood (TSA-B) (VVR, Mississauga, ON, Canada) and incubated 16–72 h at 37°C for isolation of M. haemolytica, P. multocida, and T. pyogenes. For the isolation of H. somni, swabs were inoculated directly onto Chocolate Agar (VWR, Mississauga, ON, Canada) and incubated for 16–72 h at 37°C with 5% CO₂. For isolation of M. bovis, swabs were inoculated directly on either heart infusion agar (Becton Dickenson, Sparks, MD, USA) containing 500 µg/mL ampicillin or modified Eaton’s Agar (13) containing 500 µg/mL ampicillin and incubated for 120 h at 37°C with 5% CO₂.

Tissue samples were manually homogenized in 10 mL of brain heart infusion (BHI) broth for approximately 1 min or until even consistency was achieved. Both the homogenized tissue suspensions and raw fluid samples were serially diluted 1:10 in BHI broth. For isolation of M. haemolytica, P. multocida, and T. pyogenes, 100 µL of the 10⁻¹ and 10⁻² dilutions were each inoculated onto TSA-B, and on Chocolate Agar for the isolation of H. somni with the culture conditions as specified above. For isolation of M. bovis, the diluted, homogenized tissue suspensions, or joint fluid samples were each filtered through a coarse, large pore filter and then through a 0.45 µm filter syringe. A 100 µL aliquot of the resulting filtrate was added to 10 mL of sterile heart infusion (HI) broth containing 500 µg/mL ampicillin. Subsequently, a 100 µL of the resulting diluted, filtered sample was inoculated directly on either HI Agar containing 500 µg/mL ampicillin, or

| TABLE 1 | Variables collected for animals entered in the study. |
|-----------------|--------------------------------------------------|
| Descriptor      | Description                                      |
| Animal identification number |                                          |
| Ear tag number  |                                                  |
| Veterinary practice code |                                             |
| Farm            |                                                  |
| Region          |                                                  |
| Alive? (True or false) |                                              |
| Animal type (fall calves, winter calves, yearlings, adults) | |
| Number of days on feed |                                              |
| Field diagnosis/diagnoses |                                      |
| Treatment on arrival |                                            |
| Additional treatment(s) |                                         |
modified Eaton’s Agar containing 500 µg/mL ampicillin, and incubated for 120 h at 37°C with 5% CO₂.

Species Confirmation
Isolates displaying appropriate morphologies for *Mycoplasma, M. haemolytica, P. multocida,* and *H. somni* were species confirmed using Matrix Assisted Laser Desorption/Ionization-Time of Flight (Maldi-Tof) Mass Spectroscopy (microflex™ LT/SH Maldi-TOF, Bruker Corp., Milton, ON, Canada) according to manufacturer’s specifications. Resulting spectra were analyzed using Maldi BioTyper® software (Bruker Daltonik GmbH, Leipzig, Germany). Samples stored for later analysis were preserved using Microbank™ cryopreservation carriers (Pro-Lab Diagnostics, Richmond Hill, ON, Canada) following manufacturer guidelines.

Antimicrobial Susceptibility Testing (AST)
Antimicrobial susceptibility testing was performed on all isolates using broth microdilution and a commercially available bovine/porcine panel (Sensititre; Trek Diagnostic Systems, Cleveland, OH, USA) and standardized breakpoints. Briefly, all isolates were suspended in 0.9% saline to a McFarland standard of 0.5 with 10 µL of the resulting suspension used to inoculate 11 mL of Mueller-Hinton Broth with TES containing lysed horse blood (Trek Diagnostic Systems, Cleveland, OH, USA). This final suspension was used to inoculate the Sensititre plates per the manufacturer’s instructions. For *M. haemolytica, P. multocida,* and *T. pyogenes,* plates were sealed and incubated at 34−37°C aerobically for 18−24 h. *H. somni* and *M. bovis* plates were sealed

---

**TABLE 2** Samples collected, isolates recovered, and isolates used in susceptibility analysis (n = 618 animals).

| Sample          | Isolate              | No. isolates | % recovery | No. isolates with antimicrobial resistance results |
|-----------------|----------------------|--------------|------------|---------------------------------------------------|
| Lung (n = 480)  | Mannheimia haemolytica | 213          | 44.4       | 208                                                |
|                 | Mycoplasma bovis     | 198          | 41.3       | 194                                                |
|                 | Pasteurella multocida| 86           | 17.9       | 85                                                 |
|                 | Histophilus somni    | 64           | 13.3       | 63                                                 |
|                 | Trueperella pyogenes | 69           | 14.4       | 69                                                 |
| Pleural fluid (n = 20) | *M. haemolytica*       | 7            | 35         | 7                                                  |
|                 | *M. bovis*           | 1            | 5          | 1                                                  |
|                 | *P. multocida*       | 0            | 0          | 0                                                  |
|                 | *H. somni*           | 1            | 5          | 1                                                  |
|                 | *T. pyogenes*        | 0            | 0          | 0                                                  |
| Nasal swab (n = 75) | *M. haemolytica*       | 14           | 18.7       | 6                                                  |
|                 | *M. bovis*           | 8            | 10.7       | 7                                                  |
|                 | *P. multocida*       | 15           | 20         | 15                                                 |
|                 | *H. somni*           | 2            | 2.7        | 2                                                  |
|                 | *T. pyogenes*        | 0            | 0          | 0                                                  |
| Deep nasal swab (n = 71) | *M. haemolytica*       | 15           | 21.1       | 10                                                 |
|                 | *M. bovis*           | 16           | 22.5       | 16                                                 |
|                 | *P. multocida*       | 15           | 21.1       | 15                                                 |
|                 | *H. somni*           | 5            | 7          | 3                                                  |
|                 | *T. pyogenes*        | 15           | 21.1       | 15                                                 |
| Laryngeal/tracheal swab (n = 4) | *M. haemolytica*       | 0            | 0          | 0                                                  |
|                 | *M. bovis*           | 1            | 25         | 1                                                  |
|                 | *P. multocida*       | 1            | 25         | 1                                                  |
|                 | *H. somni*           | 1            | 5          | 0                                                  |
|                 | *T. pyogenes*        | 2            | 50         | 2                                                  |
| Heart/pericardium (n = 18) | *M. haemolytica*       | 1            | 5.5        | 1                                                  |
|                 | *M. bovis*           | 4            | 22.2       | 2                                                  |
|                 | *P. multocida*       | 0            | 0          | 0                                                  |
|                 | *H. somni*           | 6            | 33.3       | 5                                                  |
|                 | *T. pyogenes*        | 1            | 5.4        | 1                                                  |
| Peritoneum (n = 1) | *M. haemolytica*       | 0            | 0          | 0                                                  |
|                 | *M. bovis*           | 1            | 100        | 1                                                  |
|                 | *P. multocida*       | 0            | 0          | 0                                                  |
|                 | *H. somni*           | 0            | 0          | 0                                                  |
|                 | *T. pyogenes*        | 0            | 0          | 0                                                  |
| Joint fluid (n = 70) | *M. haemolytica*       | 1            | 1.4        | 1                                                  |
|                 | *M. bovis*           | 4            | 5.7        | 3                                                  |
|                 | *P. multocida*       | 0            | 0          | 1                                                  |
|                 | *H. somni*           | 1            | 1.4        | 0                                                  |
|                 | *T. pyogenes*        | 7            | 10         | 7                                                  |
| Abscess (n = 1) | *M. haemolytica*       | 0            | 0          | 0                                                  |
|                 | *M. bovis*           | 1            | 100        | 1                                                  |
|                 | *P. multocida*       | 1            | 100        | 0                                                  |
|                 | *H. somni*           | 1            | 100        | 1                                                  |
|                 | *T. pyogenes*        | 0            | 0          | 0                                                  |
using perforated film and incubated with 5% CO₂ at 34–37°C for 24–96 h. Minimum inhibitory concentrations (MIC50) were assigned by eye as outlined in the Clinical and Laboratory Standards Institute (14). Where CLSI breakpoints were unavailable, susceptibility was estimated from available CLSI recommendations for human pathogen/antimicrobial combinations (15).

**Analysis**

The proportion of samples positive for *M. haemolytica*, *P. multocida*, *T. pyogenes*, *H. somni*, and *M. bovis* (target organisms) and the distributions of MIC’s for each pathogen/antimicrobial combination were determined. Quantitative levels of susceptibility were measured using the 50th percentiles for MIC50. Multidrug resistance (MDR) isolates were defined as resistance observed to multiple drug classes with extreme MDR (XDR) defined as any resistance (MDR) isolates were defined as resistance observed to multiple drug classes with extreme MDR (XDR) defined as any resistance observed to multiple drug classes with extreme MDR (XDR) defined as any resistance observed to multiple drug classes with extreme MDR (XDR) defined as any resistance observed to multiple drug classes with extreme MDR (XDR) defined as any resistance observed to multiple drug classes with extreme MDR (XDR) defined as any resistance observed to multiple drug classes with extreme MDR (XDR) defined as any resistance observed to multiple drug classes with extreme MDR (XDR) defined as any resistance observed to multiple drug classes with extreme MDR (XDR) defined as any resistance observed to multiple drug classes with extreme MDR (XDR) defined as any resistance. Lacking a cell wall, *M. bovis* is inherently resistant to the β-lactams so resistance to this class was not included.

Two feedlots (Feedlot A and Feedlot B) serviced by different veterinary practices provided a substantial number of samples (15.2 and 33.2% of total samples, respectively) with which we could compare MDR profiles. For each of the pathogens, two sample Wilcoxon rank-sum test was used to compare the MDR at Feedlot A to Feedlot B.

### RESULTS

#### Animals and Samples Collected

The seven participating practices submitted samples from 60 feedlots located in 10 municipal counties in southern Alberta (*Figure 1*). Samples for microbiological analysis (*n* = 740) were collected from 618 animals (528 mortalities and 90 morbid cattle), slightly fewer than the calculated sample size. Time constraints prevented further sampling. Animal age was recorded for 76.3% of the cases and where provided, 90.5% of animals were adults (2 years and older). The number of days on feed was calculated for 86.6% of the animals, with 56.7% of these collected on feed, and 22% greater than 60 days on feed. A field diagnosis was provided for 99% of the animals with target-positive samples; 94.5% were described as pneumonia and/or pleuritis. Arthritis and pericarditis/myocarditis, usually as comorbidities, were identified in 5.7 and 3.6% of the cattle, respectively.

#### Microbiological Results

One or more of the targeted pathogens (*n* = 775) were isolated from 457 cattle and AMR susceptibility testing was completed on 745 target isolates from 441 animals (*Table 2*). Overall,

### Table 3 | Distribution of minimum inhibitory concentrations among *Mannheimia haemolytica* isolates (*n* = 219 animals, 233 samples: lung samples = 208, nasal swabs = 16, pleural fluid = 7, heart = 1, joint fluid = 1).

| Class       | Category | Antimicrobial | MIC 50 | %R | ≤0.12 | 0.25 | 0.5 | 1 | 2 | 4 | 8 | 16 | 32 | 64 |
|-------------|----------|---------------|--------|----|-------|------|-----|---|---|---|---|---|----|----|----|
| Aminoglycoside | II       | GEN           | 4      | 3.4 | 4.3  | 38.6 | 50.6 | 3.0 | 3.4 |
|             | II       | NEO           | 8      | 49.4 | 13.7 | 36.9 | 1.3 | 48.1 |
|             | III      | SPE           | 32     | 4.3  | 1.7  | 20.2 | 73.0 | 64  | 0.9 |
| Fluoroquinolone | I       | ENRO          | 0.12   | 3.0  | 94   | 1.3  | 1.3 | 0.4 | 3.0 |
|             | I        | DANO          | 0.12   | 3.9  | 91   | 4.3  | 0.9 | 3.9 |
| Macrolide    | II       | TYLT          | 32     | 99.1 | 0.4  | 0.4  | 4.3 | 94.8 |
|             | II       | TIL           | 16     | 37.8 | 4.3  | 6.9  | 14.6 | 17.6 | 14.2 | 4.7 | 37.8 |
|             | II       | NIL           | 0.25   | 0.9  | 95.6 | 0.4  | 1.7 | 0.4 | 0.9 |
|             | II       | PEN           | 0.12   | 7.2  | 51.9 | 43.5 | 4.3 | 1.7 | 0.4 | 4.7 |
|             | II       | AMP           | 0.25   | 5.1  | 22.3 | 1.3  | 1.3 | 0.9 | 0.4 | 3.4 |
| Lincosamides | II       | CLIN          | 8      | 77.7 | 0.9  | 0.9  | 2.1 | 18.5 | 57.5 | 20.2 |
|             | III      | FFN           | 1      | 4.3  | 1.7  | 39.9 | 51.1 | 2.1 | 0.9 | 4.3 |
| Tetracycline | III      | OXY           | 8      | 53.6 | 20.6 | 4.3  | 0.9 | 53.6 |
|             | III      | CTET          | 2      | 11.2 | 8.2  | 30.0 | 25.8 | 24.9 | 11.2 |
| Pleuromutilin| III      | TIA           | 16     | 19.7 | 0.4  | 1.7  | 3.9 | 9.4 | 64.8 | 19.7 |

Trimethoprim sulphad (Category II): ≤MIC50 = 98.3%, >MIC50 = 1.7%.

Sulphadimethoxine (Category III): ≤MIC50 = 44.6%, >MIC50 = 55.4%.

GEN, gentamicin/NEO, neomycin/SPE, spectinomycin; DAN, danofloxacin/ENRO, enrofloxacin; TYLT, tylosin/TIL, tulathromycin/TIL, tilmicosin; PEN, penicillin/AMP, ampicillin/XNL, ceftiofur; CLI, clindamycin; FFN, florfenicol; SXT, trimethoprim sulphadimonocetyl; XNL, sulpha/dimethoxine; OXY, oxytetracycline; CTET, chlortetracycline; TIA, tiamulin.

*Values in red indicate resistant proportion of samples.

Shaded areas indicate concentrations not tested.
TABLE 4 | Distribution of minimum inhibitory concentrations among Mycoplasma bovis isolates (n = 211 animals and 226 samples; lung samples = 194, nasal swabs = 23, laryngeal swabs = 1, pleural fluid = 1, heart = 2, joint fluid = 3, peritoneum = 1, abscess = 1).

| Class        | Category | Antimicrobial | MIC 50 | %R | ≤0.12 | 0.25 | 0.5 | 1   | 2   | 4   | 8   | 16  | 32  | 64  |
|--------------|----------|---------------|--------|-----|-------|------|-----|-----|-----|-----|-----|-----|-----|-----|
| Aminoglycoside | II       | GEN           | 16     | 68  | 1.3   | 1.3  | 8   | 31.4| 58  |
|              | II       | NEO           | 32     | 97.7| 1.3   | 0.9  | 0.4 | 97.3|
|              | III      | SPE           | 8      | 0.9 | 88.9  | 8.8  | 0.9 | 64  | 0.4 |
| Fluoroquinolone | I        | ENRO         | 0.25   | 8   | 44.2  | 41.6 | 40  | 2.2 | 8   |
|              | I        | DANO         | 0.25   | 17.7| 15.5  | 42.5 | 24.3| 17.7|
| Macrolide     | II       | TYLT         | 32     | 97.7| 0.9   | 0.4  | 0.9 | 97.3|
|              | II       | TUL          | 64     | 92  | 0.4   | 0.9  | 0.9 | 3.5 | 18  | 92  |
| B lactams     | II       | XNL          | 8      | 98.2| 1.8   | 98.2 |
|              | II       | PEN          | 8      | 98.6| 0.13  | 0.4  | 0.4 | 98.2|
|              | II       | AMP          | 16     | 98.6| 0.9   | 0.4  | 0.4 | 98.2|
| Lincosamides | II       | CLIN         | 16     | 73  | 8.4   | 7.1  | 6.2 | 4.0 | 1.3 | 3.1 | 69.9|
| Phenicline    | III      | FFN          | 4      | 25.7| 1.3   | 1.3  | 5.8 | 19.9| 46  | 25.7|
| Tetracycline  | III      | OXY          | 8      | 80.1| 1.3   | 0.9  | 8   | 9.7 | 80.1|
| Pleuromutilin | III      | CTET         | 8      | 69.5| 2.2   | 2.2  | 7.1 | 19  | 69.5|
|              | I        | TIA          | 1      | 2.2 | 42    | 27.9 | 11.5| 5.3 | 8.4 | 2.7 | 2.2 |

Trimethoprim sulpha (Category II): ≤0.12 = 2.2%, >0.12 = 97.8%.
Sulphadimethoxine (Category III): <256 = 40.3%, >256 = 59.7%.
GEN, gentamycin; NEO, neomycin; SPE, spectinomycin; DAN, danofloxacin; ENRO, enrofloxacin; TYLT, tylosin; TUL, tulathromycin; TIL, tilmicosin; PEN, penicillin; AMP, ampicillin; XNL, amoxicillin; NEO, neomycin; SPE, spectinomycin; KL, clindamycin; FFN, florfenicol; SXT, trimethoprim sulpha; SDM, sulphadimethoxine; OXY, oxytetracycline; CTET, chlorotetracycline; TIA, tiamulin.

*Category of Antimicrobial Drugs Based on Importance in Human Medicine—Veterinary Drug Directorate.

**Pathogen minimum inhibitory concentration breakpoints from CLSI standards.

*No CLSI breakpoint for this bovine respiratory disease pathogen/antimicrobial combination, simply notes susceptibility.

Values in red indicate resistant proportion of samples.

Shaded areas indicate concentrations not tested.

73.9% of the animals sampled resulted in recovery of a targeted pathogen. Percent recovery of the target organisms varied by sample and organism (Table 2). Lung samples returned primarily M. haemolytica and M. bovis isolates with 104 samples yielding both organisms. Of these samples, 78 (75%) of the field diagnoses were fibrinous pneumonia and the remaining samples were chronic pneumonia, bronchopneumonia, or not specified (e.g., BRD). Swab samples yielded proportionally larger populations of P. multocida than that observed in the lower respiratory tract. Trueperella pyogenes was recovered most frequently from deep nasal swab as well as from joints. Both M. bovis and H. somni were most readily isolated from heart/pericardium tissues.

Treatment data on entry to the feedlot was provided for 46.6% of the submissions and of these, to 95.5% of the animals were administered a macrolide antimicrobial. Information about in-feed antimicrobials was not collected but feedlots in Western Canada routinely add tetracyclines to the feed during the early (approximately 10–20 days) feeding period for BRD prevention, and either tylosin or tetracyclines throughout the feeding period for liver abscess control (C. Dorin, personal communication, November 2015).

Antimicrobial Resistance
There was AMU information provided for 444 treatments from 235 (38%) animals. The number of antimicrobial treatments per animal, including entry, ranged from 1 to 5. The average number of antimicrobial classes represented in the treatments was 1.86 (SD, 0.99). In the cattle selected for treatment, florfenicol was used in 35.4% of cases, enrofloxacin in 27.5%, and ceftiofur in 14%. Macrolides (8.8%), tetracyclines (7.4%), and trimethoprim sulfa (7.0%) were used in the remaining treated cattle.

The distributions of the MICs for the five target organisms are provided in Tables 3–7. Based on the breakpoints used, there was a low frequency of resistance to the Category I antimicrobials (agents of very high importance to human health—ceftiofur, enrofloxacin, and danofloxacin). However, a high frequency of resistance to Category II antimicrobials (high importance to human health—neomycin, tylosin, tulathromycin, tilmicosin, and clindamycin), was observed especially among M. haemolytica, M. bovis, and P. multocida isolates.

Analysis
The frequencies of multiclass resistance in the isolates are shown in Table 8. Multidrug resistance was high in all the BRD pathogens with 95.6% resistant to two or more classes and 47.2% resistant to four or five antimicrobial classes. Extreme multidrug resistance occurred in 9.9% of M. haemolytica, 30.5% of M. bovis, 41% of P. multocida, 6.7% of H. somni and 36.2% of T. pyogenes isolates. M. haemolytica had the highest degree of XDR, with six isolates resistant to eight to nine drug classes. Because of its importance
TABLE 5 | Distribution of minimum inhibitory concentrations among Pasteurella multocida isolates (n = 113 animals and 117 samples; lung samples = 85, nasal swabs = 30, laryngeal swabs = 1, joint fluid = 1).

| Class          | Category | Antimicrobial | MIC 50 (µg/ml) | %R | ≤0.12 | 0.25 | 0.5 | 1 | 2 | 4 | 8 | 16 | 32 | 64 |
|----------------|----------|---------------|----------------|----|-------|------|-----|---|---|---|---|----|----|----|
| Aminoglycoside | **II**   | GEN           | 4              | 8.5 |       | 8.5  | 53.0 | 29.9 | 8.5 |        |     |     |     |    |
|                | **II**   | NEO           | 16             | 65.8 |       | 5.1  | 29.1 | 28.2 | 37.6 |        |     |     |     |    |
|                | **III**  | SPE           | 32             | 27.4 |       | 1.7  | 36.8 | 32.5 | 64 >64 | 1.7 | 27.4 |     |    |
| Fluoroquinolone| **I**    | ENRO          | 0.12           | 1.7  | 88.9  | 6.8  | 2.6  | 1.7 |     |     |     |     |     |    |
|                | **I**    | DANO          | 0.12           | 1.7  |       | 94.9 | 30.8 | 11.1 | 5.1 | 7.7 | 1.7 | 29.9 |     |    |
| Macrolide      | **II**   | TYLT          | 32             | 99.1 |       | 6.8  | 92.3 |     |     |     |     |     |     |    |
|                | **II**   | TUL           | 4              | 29.9 |       | 13.7 | 30.8 | 11.1 | 5.1 | 7.7 | 1.7 | 29.9 |     |    |
|                | **II**   | TIL           | 16             | 41.9 |       | 12.9 | 33.3 | 12.0 | 0.9 | 41.0 |     |     |     |    |
| B lactams      | **II**   | XNL           | 0.25           | 1.7  | 30.8  | 56.4 | 11.1 |     |     |     |     |     |     |    |
|                | **II**   | PEN           | 0.25           | 1.7  |       |      | 1.7  |     |     |     |     |     |     |    |
|                | **II**   | AMP           | 0.25           | 1.8  |       | 72.6 | 24.8 | 0.9 | 0.9 |     |     |     |     |    |
| Lincosamides   | **II**   | CLIN          | 16             | 100  |       |     |     |     |     |     |     |     |     |    |
| Tetracycline    | **III**  | FFN           | 0.5            | 1.7  |       | 10.3 | 58.1 | 4.3 |     |     |     |     |     |    |
|                  | **III**  | OXY           | 8              | 55.6 |       | 29.1 | 7.7  | 3.4 | 4.3 | 55.6 |     |     |     |    |
|                  | **III**  | CTET          | 4              | 43.6 |       | 16.2 | 21.4 | 11.1 | 7.7 | 43.6 |     |     |     |    |
| Pleuromutin     | **II**   | TIA           | 32             | 86.3 |       | 0.9  | 12.0 | 86.3 |     |     |     |     |     |    |

Trimethoprim sulpha (Category II): ≤2/38 = 76.1%, >2/38 = 23.9%.
Sulphadimethoxine (Category III): ≤256 = 35.9%, >256 = 64.1%.
GEN, gentamycin/NEO, neomycin/SPE, spectinomycin; DAN, danofloxacin; ENRO, enrofloxacin; TYLT, tylosin/TIL, tilmicosin; PEN, penicillin/AMP, ampicillin/XNL, cellotri; CLIN, clindamycin; FFN, florfenicol; XNL, xylanil; DANO, danofloxacin; NEO, neomycin; SPE, spectinomycin; "TIA, tiamulin.

cCategorization of antimicrobial drugs based on importance in human medicine—Veterinary Drug Directorate.

αPathogen minimum inhibitory concentration breakpoints from CLSI standards.

No CLSI breakpoint for this bovine respiratory disease pathogen/antimicrobial combination, simply notes susceptibility.

Values in red indicate resistant proportion of samples. Shaded areas indicate concentrations not tested.

as a therapy for BRD, the frequency of BRD isolates that exhibited multidrug resistance that included tulathromycin resistance are presented in Table 9.

We compared the distribution of the MDR for the isolates at Feedlot A and Feedlot B (Table 10). Feedlot B had a significantly (α = 0.05) higher rate of resistance between for M. haemolytica (z (96) = 3.788, p = 0.0002) and P. multocida (z (57) = -3.183, p = 0.0015).

DISCUSSION

This study was a successful collaboration of private practice veterinarians, industry, government, and a diagnostic laboratory for monitoring AMR in BRD pathogens from feedlot cattle in southern Alberta and quantified the phenotypic AMR in BRD-affected feedlot cattle.

Most animals in this study were calves that had arrived at the feedlots within the previous 60 days would be considered classical cases of shipping fever. M. haemolytica is consistently associated with the acute form of fibrinous pneumonia (16), and it is anticipated that it would be the most frequently isolated bacterium from respiratory tract samples. From lung tissues, M. bovis was recovered in almost equal numbers to M. haemolytica; fibrinous pneumonia, characteristic of M. haemolytica, was diagnosed in 75% of cases where both these bacteria were isolated; bronchopneumonia is classically associated with M. bovis infection (17). P. multocida was recovered more frequently than M. bovis from nasal swab samples. This is likely a reflection of P. multocida’s ability to competitively exclude other microflora in complex niches and thus thrive in mixed bacterial communities in the nasopharynx (18). Given that T. pyogenes and H. somni are more frequently associated with systemic infection (19, 20), it is not surprising that we isolated these bacteria more frequently from lung tissue, heart/pericardium, and joint samples than nasopharyngeal swabs.

Difficulties can arise when comparing microbial prevalence data between BRD studies due to the complex etiology of this illness, inconsistencies in the specific agents targeted among studies, and the effects that differing sampling and lab processing strategies have in recovery rates. For example, comparisons against similar surveillance of BRD mortalities performed by Klima et al. (8) report a 74% recovery of M. haemolytica from diseased lung tissue, while samples examined by Fulton et al. (21) showed a 25% recovery rate for M. haemolytica, a number more in line with the 33% recovery rate observed here. However, immunohistochemical staining performed by Booker et al. (2) suggested the presence of M. haemolytica in >90% of cases of purulent, acute, and subacute forms of pneumonia. The same study found M. bovis in 40–50% of acute cases while being far more predominant (90% recovery) in fatal, chronic cases of...
BRD. Overall, the trends in this dataset reflect what is expected of pneumonia typically exhibited in calves within 60 days of arrival; a larger proportion of Pasteurellaceae species and a lesser presence of H. somni and T. pyogenes. The abundance of M. bovis in all body sites examined and its co-isolation with other BRD organisms in 205 of 226 BRD cases in this study has also been reported elsewhere (16).

Sixty-six percent of H. somni isolates and all isolates of M. haemolytica, P. multocida, T. pyogenes, and M. bovis were resistant to at least one of the antimicrobials tested, with the majority of all isolates (90.2%) resistant to at least one of the three macrolide drugs tested. Macrolides are currently used for metaphylaxis in groups of high-risk calves at arrival into feedlots and as direct therapies for BRD cases. The levels of resistance seen to macrolide drugs in this study are of concern given both the extent to which the bacteria are resistant. The levels of XDR observed in this study in conjunction with the high prevalence of tulathromycin and oxytetracycline resistance observed indicate that the use of either macrolides or tetracycline drugs for preventing Trueperella may be ineffective.

High levels of resistance (>80%) were also observed against tiamulin (TIA) in the P. multocida isolates but not in the other bacterial species examined. Tiamulin is a pleuromutilin drug that is used in-feed for swine production as it can prevent swine dysentery, porcine spirochetosis, and Pasteurella associated pneumonia. P. multocida resistance to tiamulin has been observed in swine lung samples (23). The TIA resistance observed here combined with a lack of pleuromutilin use in beef production systems raises the question as to the origin of some of the AMR observed in this study.

In North America, there is a trend toward increasing frequencies of MDR in pathogens involved in high mortality BRD cases (6, 8, 24, 25). Recent reports examining the molecular basis for AMR in Pasteurellaceae strains from BRD mortalities indicate that large mobile elements, linking arrays of resistance genes together, are present in both American and Canadian fed cattle populations (10, 26). These linked AMR genes can be readily promoted and/or maintained by co-selection using any drug to which the bacteria are resistant. The levels of XDR observed in this study in conjunction with the high prevalence of tulathromycin and oxytetracycline resistance observed indicate that the frequent use of these drugs could be selecting for XDR isolates in feedlots. Further genetic characterization will be required for confirmation but the consequences for therapeutic recommendations are important and an issue that will need to be examined further to determine the most effective means to successfully

### TABLE 6 | Distribution of minimum inhibitory concentrations among Histophilus somni isolates \( n = 72 \) animals and 75 samples, lung samples \( n = 63 \), nasal swabs \( n = 5 \), pleural fluid \( n = 1 \), heart/pericardium \( n = 5 \), abscess \( n = 1 \).

| Class | Category* | Antimicrobial | MIC 50 | MIC 90 | %R | ≤0.12 | 0.25 | 0.5 | 1 | 2 | 4 | 8 | 16 | 32 | ≥64 |
|-------|-----------|---------------|--------|--------|-----|-------|------|-----|---|---|----|----|-----|----|-----|-----|
| Aminoglycoside | II | GEN | 8 | 32.0 | 8.0 | 9.3 | 20.0 | 30.7 | 32.0 | | | | | | |
| | II | NEO | 32 | 85.3 | 5.3 | 9.3 | 13.3 | 72.0 | | | | | | | | |
| | III | SPE | 16 | 10.7 | 17.3 | 48.0 | 24.0 | 10.7 | | | | | | | | |
| Fluorquinolone | I | ENRO | 0.12 | 4.0 | 88.0 | 1.3 | 1.3 | 5.3 | 4.0 | | | | | | | |
| | I | DANO | 0.12 | 10.7 | 84.0 | 5.3 | | | | | | | | | | |
| Macrolide | III | TYLT | 8 | 34.6 | 2.7 | 5.3 | 13.3 | 24.0 | 20.0 | 21.3 | 13.3 | | | | | |
| | III | TUL | 8 | 21.3 | 2.7 | 10.7 | 33.3 | 25.3 | 6.7 | 21.3 | | | | | | |
| | III | TIL | 4 | 18.7 | | | | | | | | | | | | |
| B lactams | I | XNL | 0.25 | 0 | 97.3 | 2.7 | | | | | | | | | | |
| | II | PEN | 0.12 | 13.3 | 84.0 | 2.7 | 4.0 | 4.0 | 5.3 | | | | | | | |
| | II | AMP | 0.25 | 11.9 | 85.3 | 2.7 | 5.3 | 1.3 | 1.3 | 4.0 | | | | | | |
| Lincosamides | II | CLIN | 1 | 12.0 | 13.3 | 37.3 | 32.0 | 4.0 | 1.3 | 12.0 | | | | | | |
| Phenicol | III | FFN | 0.25 | 1.3 | 78.7 | 9.3 | 10.7 | | | | | | | | | |
| Tetracycline | III | OXY | 8 | 54.7 | 20.0 | 4.0 | 10.7 | 10.7 | | | | | | | | |
| | III | CTET | 2 | 16.0 | 26.7 | 10.7 | 22.7 | 24.0 | 16.0 | | | | | | | |
| Pleuromutilin | TIA | 1 | | | | | | | | | | | | | | |

* | \(| n = 2/38 = 97.3\% \), \(| n = 2/38 = 2.7\% \).*

| Class | Category* | Antimicrobial | MIC 50 | MIC 90 | %R | ≤0.12 | 0.25 | 0.5 | 1 | 2 | 4 | 8 | 16 | 32 | ≥64 |
|-------|-----------|---------------|--------|--------|-----|-------|------|-----|---|---|----|----|-----|----|-----|-----|
| Aminoglycoside | II | GEN | 8 | 32.0 | | 8.0 | 9.3 | 20.0 | 30.7 | 32.0 | | | | | | |
| | II | NEO | 32 | 85.3 | | 5.3 | 9.3 | 13.3 | 72.0 | | | | | | | |
| | III | SPE | 16 | 10.7 | | 17.3 | 48.0 | 24.0 | 10.7 | | | | | | | |
| Fluorquinolone | I | ENRO | 0.12 | 4.0 | | 88.0 | 1.3 | 1.3 | 5.3 | 4.0 | | | | | | |
| | I | DANO | 0.12 | 10.7 | | 84.0 | 5.3 | | | | | | | | | |
| Macrolide | III | TYLT | 8 | 34.6 | | 2.7 | 5.3 | 13.3 | 24.0 | 20.0 | 21.3 | 13.3 | | | | |
| | III | TUL | 8 | 21.3 | | 2.7 | 10.7 | 33.3 | 25.3 | 6.7 | 21.3 | | | | | |
| | III | TIL | 4 | 18.7 | | | | | | | | | | | | |
| B lactams | I | XNL | 0.25 | 0 | | 97.3 | 2.7 | | | | | | | | | |
| | II | PEN | 0.12 | 13.3 | | 84.0 | 2.7 | | | | | | | | |
| | II | AMP | 0.25 | 11.9 | | 85.3 | 2.7 | | | | | | | | |
| Lincosamides | II | CLIN | 1 | 12.0 | | 13.3 | 37.3 | | | | | | | | |
| Phenicol | III | FFN | 0.25 | 1.3 | | 78.7 | 9.3 | | | | | | | | |
| Tetracycline | III | OXY | 8 | 54.7 | | 20.0 | | | | | | | | | |
| | III | CTET | 2 | 16.0 | | 26.7 | | | | | | | | | |
| Pleuromutilin | TIA | 1 | | | | | | | | | | | | | | |
TABLE 7 | Distribution of minimum inhibitory concentrations among *Trueperella pyogenes* isolates (*n* = 83 animals and 94 samples; lung samples = 69, nasal swabs = 15, laryngeal swab = 2, heart/pericardium = 1, joint fluid = 7).

| Class                   | Category | Antimicrobial | MIC 50 | %R | ≤0.12 | 0.25 | 0.5 | 1  | 2  | 4  | 8  | 16 | 32 | ≥64 |
|-------------------------|----------|---------------|--------|----|-------|------|-----|----|----|----|----|----|----|-----|
| Aminoglycoside II       | GEN      | 1             | 9.6    |    | 83.0  | 3.2  | 2.1 | 2.1| 9.6|
|                         | NEO      | 4             | 9.6    |    |       |      |     |    |    |    |    |    |    |     |
|                         | SPE      | 8             | 1.1    |    |       |      |     |    |    |    |    |    |    |     |
| Fluoroquinolone I       | ENRO     | 1             | 0      | 43.6| 54.3  |      |     |    |    |    |    |    |    |     |
|                         | DANO     | 1             | 91.5   | 3.2| 5.3   | 91.5 |      |    |    |    |    |    |    |     |
| Macrolide II            | TYLT     | 32            | 79.7   | 16.0| 1.1   |      | 3.2 | 10.6| 69.1|
|                         | TUL      | 64            | 57.4   | 23.4| 4.3   | 3.2  | 5.3 | 5.3| 1.1| 57.4|
|                         | TIL      | 64            | 75.6   | 22.3| 2.1   |      | 1.1 | 74.5|
| B lactams               | XNL      | 0.5           | 1.1    | 12.8| 40.4  | 42.6 | 2.1 | 1.1| 1.1|
|                         | PEN      | 0.12          | 1.1    | 94.7| 2.1   | 2.1  |    |    |    | 1.1|
|                         | AMP      | 0.25          | 1.1    | 95.8| 2.1   | 2.1  |    |    |    |    | 1.1|
| Lincosamides II         | CLIN     | 16            | 83.0   | 12.8| 2.1   | 1.1  | 1.1|    |    |    |    |     | 83.0|
|                         | FFN      | 1             | 30.9   | 2.1| 25.5  | 7.4  | 6.4| 30.9|
| Tetracycline III        | OXY      | 8             | 94.7   | 1.1| 2.1   |      | 2.1| 94.7|
|                         | CTET     | 8             | 92.6   | 2.1| 3.2   | 2.1  |    | 92.6|
| Pleuromutilin III       | TIA      | 0.5           | 1.1    | 93.6| 1.1   | 1.1  | 3.2| 1.1|

Trimethoprim sulpha* (Category II): <2/38 = 98.9%, >2/38 = 1.1%.
Sulphadimethoxine* (Category III): <256 = 18.1%, >256 = 81.9%.
GEN, gentamycin/NEO, neomycin/SPE, spectinomycin/DAN, danofloxacin/ENRO, enrofloxacin/TYL, tylosin/TUL, tulathromycin/TIL, tilmicosin/PEN, penicillin/AMP, ampicillin/XNL, ceftiofur/CLI, clindamycin/FFN, florfenicol/SXT, trimethoprin sulpha/SDM, sulphadimethoxine/OXY, oxytetracycline/CTET, chlorotetracycline/TIA, tiamulin.

*Category of antimicrobial drugs based on importance in human medicine—Veterinary Drug Directorate.

Pathogen minimum inhibitory concentration breakpoints from CLSI standards.

Values in red indicate resistant proportion of samples.

Shaded areas indicate concentrations not tested.

TABLE 8 | Number of antimicrobial classes in resistance patterns for important Bovine respiratory disease pathogens.

| Isolate                     | Number of isolates | Number of isolates by number of antimicrobial classes in the resistance pattern |
|-----------------------------|--------------------|--------------------------------------------------------------------------------|
| Mannheimia haemolytica      | 233                | 1 14 88 107 17 6                                                                 |
| Mycoplasma bovis            | 226                | 0 1 18 138 69 0                                                                |
| Pasteurella multocida       | 117                | 0 0 24 45 48 0                                                                |
| Histophilus somni           | 75                 | 3 14 33 20 5 0                                                                |
| Trueperella pyogenes        | 94                 | 0 0 18 42 34 0                                                                |

Currently, macrolides are the industry’s standard for BRD preventative therapy, but the data here suggests that this may have to change in the future to effectively maintain animal health. However, the need to identify both MDR and understand the consequences for intrinsic resistance in some of the bacteria involved in BRD is important. For example, tulathromycin-resistant isolates were co-resistant to oxytetracycline, chlorotetracycline, neomycin, and/or sulphadimethoxine, suggesting that the use of any of these antimicrobials as secondary therapies would likely have resulted in treatment failure. Additionally, the use of ceftiofur for treatment of *M. haemolytica* would be a logical choice given the low levels of ceftiofur resistance observed. However, ceftiofur is a Category I drug and widespread use in cattle could be seen as imprudent. Furthermore, *M. bovis* is intrinsically resistant to ceftiofur and if adopted *en masse*, the use of this drug could potentially open an environmental niche for this species, increasing the incidence of *M. bovis* pneumonia.

Extreme multidrug resistance was identified in 24% and resistance to eight or nine classes in 0.81% of the isolates. These isolates are significant for further genotypic research and may not have been recovered with less extensive sampling strategies. The capacity to detect important changes in AMR patterns within circulating bacterial strains is enhanced with molecular subtyping and identification of integrative conjugative elements within XDR strains. With further research, identifying relatively rare XDR strains circulating in the population may be possible if targeted (risk-based) sampling if the characteristics that influence the probability of an animal carrying XDR strains can be identified. The role of metagenomic sequencing in identifying AMR within the larger animal population is also one that will need to be examined. If used appropriately, some of the newer genomics based technologies might be able to help overcome some of the burden associated with microbiological surveillance methods.

It is important to note that, in this study, the cohorts were diseased animals and may not be representative of the broader cattle population that includes healthy and diseased animals. This study
Anholt et al.  
AMR in Feedlot Cattle

selected animals suspected of having BRD or at postmortem and many would have received multiple antimicrobials. Susceptible strains of the target organisms would have been removed from the sample resulting in a higher proportion of resistant isolates. Klima et al. (8) also reported the proportions of pathogens and AMR-pathogens in BRD-affected animals in Alberta, but this study was limited to mortalities. As with most surveillance studies, using the number of isolates recovered as the denominator (proportion) rather than the source population (rate) can bias the results if the isolates vary with the animal population sampled. However, feedlots represent dynamic populations and determining the appropriate population for the denominator may not be possible. Differences such as the timing and use of vaccinations, AMU at the cow-calf level, pre-weaning, ranch-direct or sales yard source, and distance traveled, make identifying “like” populations difficult. Collecting more epidemiological data for each isolate undergoing AMR testing would help to examine and manage these biases (27).

Antimicrobial resistance patterns varied between Feedlot A and Feedlot B. Feedlot A’s veterinarian did not provide AMU data, so it was not possible to characterize the different proportions of AMR seen at each feedlot in terms of AMU. Additional information about how and where the cattle were sourced and different animal management practices could also be useful for understanding variable AMR patterns. This finding highlights the challenge of identifying a representative sample from a region and the complexity of AMR surveillance. Questions remain about the appropriate sample size for AMR studies. AMR has been shown to cluster, influenced by the ecology of the location (28). Therefore, some authors advocate small numbers of samples from many farms to monitor AMR (29). Our results demonstrated heterogeneity of the resistance patterns within, as well as between feedlots, suggesting that generating a representative sample necessitates the sampling of a considerable number of feedlots and animals within feedlot. Bootstrapping methods for examining the influence of different variance estimates and constructing confidence intervals around an estimated prevalence at both the group-level and individual level have been used to determine sufficient sample sizes for AMR studies (30).

Substantial effort and cost is required to collect samples and the associated epidemiological data as well as complete microbiological testing. To promote the optimum use of public resources, AMR surveillance systems must balance benefits with costs and

---

**TABLE 9**  Number of isolates resistant to tulathromycin as well as other antimicrobials.

| Pathogen                  | Feedlot A          | Feedlot B          | Total       |
|---------------------------|--------------------|--------------------|-------------|
| Mannheimia haemolytica    | 88 (37.8)          | 208 (92)           | 35 (29.9)   |
| Mycoplasma bovis          | 4                  | 2                  | 16 (21.3)   |
| Pasteurella multocida     | 35                 | 1                  | 54 (57.4)   |

| Number of isolates resistant to | TUL 88 | SPE 9 | GEN 8 | NEO 78 | ENRO 6 | DANO 7 | TYLT 88 | TIL 85 | PEN 9 | AMP 8 | XNL 1 | CLI 58 | FNX 7 | SXT 76 | TMS 1 | OXY 80 | CTET 19 | TIA 15 |
|-------------------------------|--------|-------|-------|--------|--------|--------|---------|--------|-------|-------|-------|--------|-------|--------|--------|---------|---------|--------|
|                              | 29     | 1     | 125   | 204    | 17     | 39     | 204     | 207    | 207   | 207   | 206   | 120    | 57    | 128    | 57     | 151     | 172     | 5      |
| Number of isolates also resistant to |       | SPE 1 | GEN 125 | NEO 34 | ENRO 0 | DANO 35 | TYLT 35 | TIL 35 | PEN 35 | AMP 0 | XNL 0 | CLI 35 | FNX 2 | SXT 33 | TMS 21 | OXY 32 | CTET 18 | TIA 34 |
|                              | 4      | 4     | 35    | 35     | 0      | 0      | 35      | 35     | 35    | 35    | 0     | 35     | 2     | 33     | 2      | 11      | 8       | 0      |

---

**TABLE 10**  Comparing the number of antimicrobial classes to which the target organisms were resistant at Feedlot A and Feedlot B using the two sample Wilcoxon rank-sum test.

| Pathogen                  | Feedlot A          | Feedlot B          | p-Value  |
|---------------------------|--------------------|--------------------|----------|
| Mannheimia haemolytica    | 0                  | 4                  | 0.0002    |
| Mycoplasma bovis          | 0                  | 1                  | 0.810     |
| Pasteurella multocida     | 0                  | 0                  | 0.0015    |
| Histophilus somni         | 0                  | 2                  | 0.978     |
| Trueperella pyogenes      | 0                  | 2                  | 0.675     |

---

---
consider alternative designs to generate the most meaningful data and meet the purpose of the system.

Further studies are required to investigate the epidemiological factors that contributed to AMR. Prospective cohort studies that can accurately measure AMU in the individual, its source herd, and other epidemiological factors commonly associated with BRD, could provide measures of associations between exposures and AMR. Notably, there have been relatively few observational studies or randomized trials comparing interventions to manage AMR in veterinary medicine (31–33).

As was seen here, it can be difficult to motivate veterinary practices to provide AMU data. This is an issue that may need to be resolved in the future before real progress can be made toward AMR intervention in the agricultural setting as collection of AMR data in isolation of AMU is of little value in terms of developing strategies that help control the spread of resistance (34). Continued collaboration within and between agriculture and public sectors is necessary for AMU and AMR surveillance, collection of animal health and management information, and data to determine the success of interventions.

Antimicrobial resistance surveillance in beef production can be challenging, specifically when trying to encompass both animal and regional variability. In addition, obtaining both animal metadata and treatment histories from private veterinary practices can be difficult with constraints on veterinary practitioners’ time and reluctance to share information. This study successfully provides an estimate of the current magnitude of AMR in BRD-affected feedlot cattle in Alberta, encompassing samples from a wide geographic range that are representative of different veterinary practices from this region. The results demonstrated the challenge of effective antimicrobial management in these animals.

ETHICS STATEMENT

This study was exempt from Animal Care Review. This was an observational, cross-sectional study. The animals that were sampled for the study were ill or had died of naturally occurring BRD. Most of the animals examined were mortalities. Sample collection from morbid animals was considered within the normal scope of practice.

REFERENCES

1. Snowden G, Van Bleek L, Cundiff L, Bennett G. Bovine respiratory disease in feedlot cattle: environmental, genetic and economic factors. J Anim Sci (2006) 84:1999–2008. doi:10.2527/jas.2006-046
2. Booker CW, Abutarbush SM, Morley PS, Jim GK, Pittman TJ, Schunicht OC, et al. Microbiological and histopathological findings in cases of fatal bovine respiratory disease of feedlot cattle in Western Canada. Can Vet J (2008) 49:473.
3. Confer AW. Update on bacterial pathogenesis in BRD. Anim Health Res Rev (2009) 10:145. doi:10.1017/S146625230990193
4. Checkley SL, Campbell JR, Chirino-Trejo M, Janzen ED, Waldner CL. Associations between antimicrobial use and the prevalence of antimicrobial resistance in fecal Escherichia coli from feedlot cattle in western Canada. Can Vet J (2010) 51:853–61.
5. Portis E, Lindeman C, Johansen L, Stoltman G. A ten-year (2000–2009) study of antimicrobial susceptibility of bacteria that cause bovine respiratory disease complex—Mannheimia haemolytica, Pasteurella multocida, and Histophilus somni—in the United States and Canada. J Vet Diagn Invest (2012) 24:932–44. doi:10.1177/1040638712457559
6. Lubbers BV, Hanzlik GA. Antimicrobial multidrug resistance and co-resistance patterns of Mannheimia haemolytica isolated from bovine respiratory disease cases – a three-year (2009–2011) retrospective analysis. J Vet Diagn Invest (2013) 25:413–7. doi:10.1177/1040638713485227
7. Noyes N, Benedict K, Gow S, Booker C, Hannon S, McAllister T, et al. Mannheimia haemolytica in feedlot cattle: prevalence of recovery and associations with antimicrobial use, resistance, and health outcomes. J Vet Intern Med (2015) 29:705–13. doi:10.1111/jvim.12547
8. Klima CL, Zaheer R, Cook SR, Booker CW, Hendrick S, Alexander TW, et al. Pathogens of bovine respiratory disease in North American feedlots conferring multidrug resistance via integrative conjugative elements. J Clin Microbiol (2014) 52:438–48. doi:10.1128/JCM.02485-13
9. Michael GB, Kadlec K, Sweeney MT, Brzuszkiewicz E, Liesegang H, Daniel R, et al. ICE Pmu1, an integrative conjugative element (ICE) of Pasteurella somni.
multicaps: analysis of the regions that comprise 12 antimicrobial resistance genes. J Antimicrob Chemother (2016) 71:597–608. doi:10.1093/jac/dkv028
10. Eidam C, Poehlein A, Leimbach A, Michael GB, Wendlandt S, Eidam C, et al. Epidemiological and comparative genomic studies of ICE Mh1, a novel integrative and con- jugative element of Mannheimia haemolytica. J Antimicrob Chemother (2014) 70:93–7. doi:10.1093/jac/dku361
11. Klima C, Alexander T, Read R, Gow S, Bookler C, Hannon S, et al. Genetic characterization and antimicrobial susceptibility of Mannheimia haemolytica isolated from the nasopharynx of feedlot cattle. Vet Microbiol (2011) 149:390–8. doi:10.1016/j.vetmic.2010.11.018
12. Holman DB, McAllister TA, Topp E, Wright A-DG, Alexander TW. The nasopharyngeal microbiota of feedlot cattle that develop bovine respiratory disease. Vet Microbiol (2015) 180:90–5. doi:10.1016/j.vetmic.2015.07.031
13. Dajani AS, Clyde WA, Denny FW. Experimental infection with Mycoplasma pneumoniae (Eaton’s agent). J Exp Med (1965) 121:1071–86. doi:10.1084/jem.121.6.1071
14. Clinical Laboratory Standards Institute. Performance Standards for Antimicrobial Disc and Dilution Susceptibility Tests for Bacterial Isolated from Animals; vet01-s4. Wayne: National Committee for Clinical Laboratory Standards (2013).
15. Clinical Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing, m100-s25. Wayne: National Committee for Clinical Laboratory Standards (2015).
16. Panceria RJ, Confer AW. Pathogenesis and pathology of bovine pneumonia. Vet Clin North Am Food Anim Pract (2010) 26:191–214. doi:10.1016/j.cvfa.2010.04.001
17. Gabinaitiene A, Nuksdaite J, Zilinskas H, Siugzdaita R, Perkevicius S. Mycoplasma bovis and bacterial pathogens in the bovine respiratory tract. Vet Med (2011) 56:28–34.
18. Bavanathasivam J, Dassanayake RP, Kugadas A, Shalhalingam S, Call DR, Knowles DP, et al. Proximity-dependent inhibition of growth of Mannheimia haemolytica by Pasteurella multocida. Appl Environ Microbiol (2012) 78:6683–8. doi:10.1128/AEM.01119-12
19. Sandal I, Hong W, Swords WE, Inzana TJ. Characterization and comparison of biofilm development by pathogenic and commensal isolates of Histophilus somni. J Bacteriol (2007) 189:8179–85. doi:10.1128/JB.00479-07
20. McDaniel CJ, Cardwell DM, Moeller RB, Gray GC. Humans and cattle: A review of bovine zoonoses. Vector-Borne Zoon Dis (2014) 14:1–19. doi:10.1099/vbz.2012.1164
21. Fulton RW, Blood KS, Panceria RJ, Payton ME, Confer AW, et al. Lung pathology and infectious agents in fatal feedlot pneumonias and relationship with mortality, disease onset, and treatments. J Vet Diagn Invest (2009) 21:464–77. doi:10.1177/1040638709320104
22. Nagaraja T, Narayanan S, Stewart G, Chengappa M. Fusobacterium necrophorum infections in animals: pathogenesis and pathogenic mechanisms. Anaerobe (2005) 11:239–46. doi:10.1016/j.anaerobe.2005.10.007
23. Lizarazo YAV, Ferri EFR, de la Fuente AJM, Martin CBG. Evaluation of changes in antimicrobial susceptibility patterns of Pasteurella multocida subsp multocida isolates from pigs in spain in 1987–1988 and 2003–2004. Am J Vet Res (2006) 67:663–8. doi:10.2460/ajvr.67.4.663
24. Katsuda K, Kohimoto M, Mikami O. Relationship between serotype and the antimicrobial susceptibility of Mannheimia haemolytica isolates collected between 1991 and 2010. Res Vet Sci (2013) 94:205–8. doi:10.1016/j.rvsc.2012.09.015
25. Snyder E, Credille B, Berghaus R, Giguere S. Prevalence of multi drug antimicrobial resistance in Mannheimia haemolytica isolated from high-risk stocker cattle at arrival and two weeks after processing. J Anim Sci (2017) 95:1124. doi:10.2527/jas.2016.1110
26. Michael GB, Freitag C, Wendlandt S, Eidam C, Feiffer AT, Lopes GV, et al. Emerging issues in antimicrobial resistance of bacteria from food-producing animals. Future Microbiol (2015) 10(3):427–43. doi:10.2217/fmb.14.93
27. Stephen C, Parmley J, Dawson-Coates J, Fraser E, Conly J. Obstacles to developing a multinational report card on antimicrobial resistance for Canada: an evidence-based review. Microb Drug Resist (2007) 13:251–60. doi:10.1089/mdr.2007.0702
28. Gibson MK, Forsberg KJ, Dantas G. Improved annotation of antibiotic resis- tance determinants reveals microbial resistomes cluster by ecology. ISME J (2015) 9:207. doi:10.1038/ismej.2014.106
29. Yamamoto T, Hayama Y, Hidano A, Kobayashi S, Muroga N, Ishikawa K, et al. Sampling strategies in antimicrobial resistance monitoring: evaluating how precision and sensitivity vary with the number of animals sampled per farm. PLoS One (2014) 9:e87147. doi:10.1371/journal.pone.0087147
30. Persoons D, Bollaerts K, Smet A, Herman L, Heyndrickx M, Martel A, et al. The importance of sample size in the determination of a flock-level antimicro- bial resistance profile for Escherichia coli in broilers. Microb Drug Resist (2011) 17:513–9. doi:10.1089/mdr.2011.0048
31. Aarestrup FM. The livestock reservoir for antimicrobial resistance: a personal view on changing patterns of risks, effects of interventions and the way for- ward. Philos Trans R Soc Lond B Biol Sci (2015) 370:20140085. doi:10.1098/rstb.2014.0085
32. Emborg H-D, Erskoll AK, Heuer OE, Wegner HC. The effect of discon- tinuing the use of antimicrobial growth promoters on the productivity in the Danish broiler production. Prev Vet Med (2001) 50:53–70. doi:10.1016/S0167-8770(01)00218-5
33. Heuer OE, Pedersen K, Jensen LB, Madsen M, Olsen J. Persistence of vanco- mycin-resistant enterococci (VRE) in broiler houses after the avoparcin ban. Microb Drug Resist (2002) 8:355–61. doi:10.1089/107662902760190680
34. Masterton R. The importance and future of antimicrobial surveillance studies. Clin Infect Dis (2008) 47:521–31. doi:10.1086/590663

Conflict of Interest Statement: RMA is the owner and director of POV Inc., a professional corporation. She was hired as a consultant, funded by the Growing Forward2 Grant, to provide expertise in the study design, analysis, and interpretation of the data, writing the report and decision to submit the report for publication. POV and MR did not receive payment from a third party for any aspect of the submitted work. She had full access to the data throughout the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. NA and MO are owners and directors of Chinook Contract Research (CCR). CCR administered the Growing Forward2 grant that covered the cost of HM-B to work as a laboratory technician on the project. CCR contributed all overhead costs associated with maintaining the grant and human resources. CCR and its directors did not receive payment from a third party for any aspect of the submitted work. The directors and HM-B had full access to the data throughout the study and take responsibility for the integrity of the data and accuracy of the data analysis. Institute of Applied Poultry Technologies (IAPT) is a not-for-profit organization of poultry industry stakeholders. At the time of the sample collection and analysis for this project, NA and MO were directors of IAPT. IAPT administered the Alberta Livestock and Meat Agency part of the grant to cover the materials costs of the project and the cost of PA to work as a laboratory technician on the project. Labor and overhead were covered as direct contributions by IAPT. IAPT and its directors did not receive payment from a third party for any aspect of the submitted work. The directors and PA had full access to the data throughout the study and take responsibility for the integrity of the data and accuracy of the data analysis. Bow Valley Research (BVR) is owned by MO. BVR was provided funds through the Growing Forward2 grant that covered the costs of Crystal Schatz to work as a laboratory technician on the project. BVR also donated technical expertise and equipment to the project. BVR and its owner did not receive payment from a third party for any aspect of the submitted work. The directors and CS had full access to the data throughout the study and take responsibility for the integrity of the data and accuracy of the data analysis. MO is owner and director of Alberta Veterinary Laboratories (AVL). AVL donated technical expertise and equipment to the project. AVL and its director did not receive payment from a third party for any aspect of the submitted work. MO had full access to the data throughout the study and take responsibility for the integrity of the data and accuracy of the data analysis. All other authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2017 Anholt, Klima, Allan, Matheson-Bird, Schatz, Ajitkumar, Otto, Peters, Schmid, Olson, McAllister and Ralston. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.